Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF…
In 2022, sales of branded biologics for respiratory indications totaled about $2.3 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032…
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Two types of pharmacotherapy are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation (…
Sarcoidosis is a rare inflammatory disease that causes the formation of granulomas—small lumps or nodules. Although it primarily affects the lungs, it can involve multiple organs, including the…
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…
Clarivate Epidemiology’s coverage of allergic rhinitis (AR) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of obstructive sleep apnea (OSA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Epi Data Slicer
The chronic obstructive pulmonary disease (COPD) therapy market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT)…